About Semax
Semax is a heptapeptide (7 amino acids) derived from the ACTH (adrenocorticotropic hormone) fragment 4-7, with three additional Pro-Gly-Pro amino acids attached. It was developed in Russia and has been the subject of research in neuroprotection and cognitive function. Unlike full-length ACTH, Semax lacks hormonal activity at adrenal receptors, making it selectively active at neurological targets.
Semax research has demonstrated significant upregulation of BDNF (brain-derived neurotrophic factor), a protein critical for neuronal survival, growth, and synaptic plasticity. It also influences NGF (nerve growth factor) expression and has been studied for effects on serotonin, dopamine, and acetylcholine systems. In animal models it has shown neuroprotective effects in ischemia models and cognitive enhancement in learning and memory tasks. Semax can be administered intranasally, making it a subject of research interest for transmucosal peptide delivery.
Research Applications
Semax is used in research investigating BDNF upregulation, neuroprotection, neurogenesis, cognitive function modulation, memory and learning, serotonin and dopamine system interactions, and intranasal peptide delivery. It is of interest in research on neurotrophic factor modulation and peptide-based approaches to neuroprotection.